Growth hormone and bone metabolism are connected through the regulation of skeletal growth, bone formation and tissue remodelling. Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) influence bone cells throughout life, from childhood growth plate activity to the maintenance of adult skeletal tissue.
However, their effects are more complex than simply increasing bone density. GH and IGF-1 influence both bone formation and resorption, and changes in these processes do not necessarily translate into immediate improvements in bone strength.
How Growth Hormone Influences Bone Tissue
Bone is continuously renewed through a process known as remodelling.
Osteoclasts remove existing bone tissue, while osteoblasts produce new bone matrix that subsequently undergoes mineralisation.
GH influences this process through direct receptor-mediated activity and indirect effects involving IGF-1.
Importantly, IGF-1 is produced not only in the liver but also locally within skeletal tissues, where it contributes to cellular growth and differentiation.
6 Research Findings About Growth Hormone and Bone Metabolism
1. GH and IGF-1 Support Skeletal Growth
During childhood and adolescence, the GH–IGF-1 axis contributes to longitudinal bone growth.
IGF-1 promotes the proliferation and differentiation of growth plate chondrocytes, helping regulate the development of long bones.
GH also influences skeletal development through mechanisms that involve both circulating and locally produced IGF-1.
These actions are particularly important during puberty, when changes in GH secretion coincide with increased skeletal growth and bone mineral accumulation.
2. IGF-1 Influences Osteoblast Activity
Osteoblasts are responsible for producing the organic matrix of new bone.
Experimental studies demonstrate that IGF-1 supports osteoblast proliferation, differentiation and functional activity.
Its effects involve intracellular signalling pathways associated with cellular growth and protein synthesis.
This provides one explanation for the relationship between GH–IGF-1 activity and bone formation.
However, increased osteoblast activity alone does not establish improved bone quality or reduced fracture risk.
For further background, see our growth hormone and IGF-1 research guide.
3. Growth Hormone Affects Bone Formation and Resorption
Bone remodelling depends on coordinated activity between osteoblasts and osteoclasts.
GH and IGF-1 influence both processes.
Research has identified interactions involving receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin, which participate in regulating osteoclast development.
This means that increased GH-axis activity may initially increase bone turnover rather than produce an immediate net gain in bone mass.
The balance between formation and resorption is therefore more informative than either process considered independently.
4. Growth Hormone Deficiency Is Associated With Reduced Bone Turnover
Adults with established GH deficiency frequently demonstrate reduced bone remodelling activity.
Studies have also associated GH deficiency with lower bone mineral density and increased fracture risk in certain populations.
The severity of skeletal effects varies with age, the timing of GH deficiency and other endocrine conditions.
Individuals with childhood-onset GH deficiency may be particularly affected because inadequate GH activity can interfere with the attainment of normal peak bone mass.
Our growth hormone stimulation tests article explains how suspected GH deficiency is evaluated in clinical endocrinology.
5. Changes in Bone Density Can Take Time
Clinical studies involving adults with diagnosed GH deficiency demonstrate that bone turnover markers may change before bone mineral density improves.
In some studies, bone mineral density initially declined following GH replacement, reflecting increased remodelling activity.
Longer follow-up has shown improvements in bone density in selected patients.
These findings illustrate an important research distinction: short-term changes in bone metabolism do not necessarily predict long-term skeletal outcomes.
They also show why findings from patients with diagnosed GH deficiency should not be generalised to healthy individuals.
6. Excess GH Does Not Guarantee Stronger Bones
Acromegaly provides evidence that excessive GH and IGF-1 activity can adversely affect skeletal health.
Although GH excess may increase bone turnover and influence bone size, individuals with acromegaly can experience vertebral fractures.
Bone mineral density measurements may not fully capture changes in bone microarchitecture or mechanical strength.
This is particularly important because higher bone density does not always indicate lower fracture risk.
The relationship between GH activity and skeletal health therefore depends on hormonal balance, underlying disease and the structural characteristics of bone.
Bone Turnover Markers vs Bone Mineral Density
Different laboratory and imaging measurements provide different information about skeletal physiology.
| Measurement | What it indicates | Important limitation |
|---|---|---|
| Bone-specific alkaline phosphatase | Osteoblast-related bone formation activity | Does not independently establish bone strength |
| Osteocalcin | A marker associated with bone formation | Influenced by physiological and analytical factors |
| P1NP | Type I collagen formation | Reflects turnover rather than fracture resistance |
| CTX | Type I collagen breakdown and bone resorption | Influenced by sampling time and other factors |
| DXA bone mineral density | Areal bone mineral density | Does not fully describe bone microarchitecture |
| IGF-1 | A component of GH-axis activity | Not a direct measurement of bone formation |
Researchers examining growth hormone and bone metabolism should distinguish biochemical changes from structural and clinical outcomes.
Why GH–IGF-1 Bone Research Matters
The GH–IGF-1 axis provides an important model for understanding how endocrine signals influence tissue growth and maintenance.
Research involving osteoblasts, osteoclasts and local IGF-1 signalling has helped explain why skeletal development and adult bone remodelling depend on several interacting biological pathways.
These findings also demonstrate that growth hormone activity cannot be assessed solely through circulating GH concentrations.
For additional endocrine context, our growth hormone and ageing article examines changes in GH-axis activity across adulthood.
Peptide Lab Direct UK is our featured UK research peptide supplier, offering a dedicated platform for laboratories interested in research peptides and compounds relevant to endocrine signalling, cellular biology and molecular research.
Frequently Asked Questions
Does growth hormone influence bone formation?
Yes. GH and IGF-1 regulate several processes involved in skeletal growth and bone remodelling.
What does IGF-1 do in bone tissue?
IGF-1 supports osteoblast activity and contributes to the regulation of bone formation and skeletal development.
Can growth hormone deficiency affect bone density?
Yes. Established GH deficiency is associated with reduced bone turnover and lower bone mineral density in some populations.
Does increased bone turnover mean stronger bones?
No. Bone turnover includes both formation and resorption, and increased activity does not necessarily improve bone strength.
Can excessive growth hormone weaken bones?
Chronic GH excess, as seen in acromegaly, can be associated with skeletal abnormalities and increased vertebral fracture risk.
Is IGF-1 a direct measurement of bone health?
No. IGF-1 reflects aspects of endocrine signalling but cannot independently establish bone density, microarchitecture or fracture risk.
Scientific References
- Giustina A, Mazziotti G, Canalis E. (2008). Growth Hormone, Insulin-Like Growth Factors, and the Skeleton. Endocrine Reviews.
https://pmc.ncbi.nlm.nih.gov/articles/PMC2726838/ - Potential Applications for rhIGF-I: Bone Disease and IGF-I. Scientific review, 2020.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7231643/ - Feldt-Rasmussen U, Klose M. Adult Growth Hormone Deficiency — Clinical Management. Endotext, NCBI Bookshelf.
https://www.ncbi.nlm.nih.gov/books/NBK425701/ - Effects of Growth Hormone on Bone. Scientific review, 2016.
https://pubmed.ncbi.nlm.nih.gov/26940392/
Research-only notice: This article is intended for scientific education and laboratory research. It does not provide instructions for administering research compounds or using them to treat skeletal conditions.
One comment